Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. (Q30850656)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

2 references

6 November 2020

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

non-small-cell lung carcinoma

20 February 2020

main subject

1 reference

6 November 2020

1 reference

6 November 2020

protein tyrosine kinase

1 reference

28 September 2019

1 reference

15 December 2019

1 reference

6 November 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

S S Kobayashi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

D B Costa

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

5 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

Brazilian Journal of Medical and Biological Research

20 February 2020

1 November 2014

1 reference

6 November 2020

9 references

3 April 2019

20 June 2019

30 June 2019

31 July 2019

14 September 2019

28 September 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

6 November 2020

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

929-939

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 3.0 Unported

20 February 2020

copyright license

8 references

3 April 2019

20 June 2019

30 June 2019

31 July 2019

14 September 2019

28 September 2019

15 December 2019

on focus list of Wikimedia project

6 November 2020

ScienceSource

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Genetics of lung-cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Lung cancer in never smokers--a different disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Management and future directions in non-small cell lung cancer with known activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Screening for germline EGFR T790M mutations through lung cancer genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

The quest to overcome resistance to EGFR-targeted therapies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Noncovalent wild-type-sparing inhibitors of EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1414-431X20144099

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230282

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230282

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230282

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4230282

Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations

25 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25296354

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Non-small cell lung cancer, version 2.2013

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25296354

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Targeting resistance in lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25296354

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1590/1414-431X20144099

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25296354%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

25296354

2 references

PubMed publication ID

25211582

27 June 2017